Growth Metrics

Biogen (BIIB) EBT Margin (2016 - 2026)

Biogen has reported EBT Margin over the past 18 years, most recently at 15.24% for Q1 2026.

  • For Q1 2026, EBT Margin rose 244.0% year-over-year to 15.24%; the TTM value through Mar 2026 reached 16.33%, down 152.0%, while the annual FY2025 figure was 15.74%, 396.0% down from the prior year.
  • EBT Margin for Q1 2026 was 15.24% at Biogen, up from 2.46% in the prior quarter.
  • Over five years, EBT Margin peaked at 54.66% in Q3 2022 and troughed at 5.58% in Q3 2023.
  • A 5-year average of 20.52% and a median of 18.29% in 2024 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: skyrocketed 4418bps in 2022 and later plummeted -6024bps in 2023.
  • Year by year, EBT Margin stood at 23.73% in 2022, then tumbled by -49bps to 12.22% in 2023, then fell by -3bps to 11.88% in 2024, then tumbled by -121bps to 2.46% in 2025, then surged by 720bps to 15.24% in 2026.
  • Business Quant data shows EBT Margin for BIIB at 15.24% in Q1 2026, 2.46% in Q4 2025, and 21.99% in Q3 2025.